<DOC>
	<DOCNO>NCT02985593</DOCNO>
	<brief_summary>The objective study evaluate safety tolerability single intravenous ( IV ) subcutaneous ( SC ) dose KHK4083 Japanese White healthy men placebo-controlled , single-blind comparative study , evaluate safety tolerability multiple IV dose KHK4083 subject ulcerative colitis open-label study .</brief_summary>
	<brief_title>A Phase 1 Study KHK4083 Healthy Volunteers Subjects With Ulcerative Colitis</brief_title>
	<detailed_description />
	<mesh_term>Ulcer</mesh_term>
	<mesh_term>Colitis , Ulcerative</mesh_term>
	<mesh_term>Colitis</mesh_term>
	<criteria>`` Part1 : 1 . Voluntary write informed consent participate study ; 2 . Japanese White men ≥20 &lt; 45 year time informed consent ; 1 . Current illness requiring treatment ; 2 . Current respiratory , gastric , renal , liver disease ; Part2 : 1 . Voluntary write informed consent participate study ; 2 . Men woman ≥20 year age time informed consent ; 3 . Ulcerative colitis diagnose ≥6 month prior inform consent ; 4 . Moderate severe ulcerative colitis ; 1 . Definitive diagnosis bacillary dysentery , amebic colitis , Salmonella enteritis , Campylobacter enteritis , colonic tuberculosis , Chlamydia enteritis , Crohn 's disease , radiation colitis , druginduced colitis , angiolymphoid hyperplasia , ischemic colitis , intestinal Behcet 's disease ; 2 . Any following clinically significant concurrent illness : Type 1 diabetes Poorly control type 2 diabetes ( HbA1c &gt; 8.5 % ) Congestive heart failure ( class II IV New York Heart Association classification ) Myocardial infarction within 1 year Unstable angina pectoris within 1 year Poorly control hypertension ( systolic pressure &gt; 150 mmHg diastolic pressure &gt; 90 mmHg screen ) Severe chronic lung disease require oxygen therapy Multiple sclerosis demyelinating disease Active malignancy , onset history treatment malignancy within 5 year prior inform consent ( except resect surgically cure epithelial carcinoma uterine cervix , cutaneous basal cell carcinoma , cutaneous squamous cell carcinoma , ductal carcinoma ) ; 3 . Current past history clinically significant cardiovascular , liver , renal , respiratory , hematologic , central nervous system , psychiatric , autoimmune diseases/disorders 2 ) ; 4 . Suspected confirm symptomatic stenosis colon , abdominal abscess , ischemic colitis base clinical radiographic data within 1 year prior enrollment ; suspect confirm toxic megacolon history toxic megacolon ; history colonic resection , subtotal total colectomy , ileostomy , colostomy ; previous surgery ulcerative colitis anticipate requirement surgery ulcerative colitis ; 5 . Known colonic dysplasia , adenoma , polyposis ( exclude benign polyposis ) ; 6 . Any planned surgical treatment study ; 7 . Clostridium difficile infection within 8 week prior enrollment ; 8 . Any active infection , include Grade ≥2 localize disease per Common Terminology Criteria Adverse Events , version 4.0 , Japan Clinical Oncology Group edition ( CTCAE v4.0JCOG ) , within 4 week prior enrollment ; 9 . Treatment 5aminosalicylic acid ( 5ASA ) enema , 5ASA suppository , steroid enema , steroid suppository within 2 week prior enrollment ; 10 . Treatment adalimumab within 2 week prior enrollment treatment infliximab within 8 week prior enrollment ;</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>